Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 06, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons under the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan transactions.
- Share Price (Ordinary): GBP 11.20
- Share Price (ADR): $44.11
- Transaction Type: Notional re-investment of dividends to be paid on July 10, 2008.
Material Changes
The filing details an increase in notional interests in Ordinary shares and Ordinary Share ADRs for specific executives following the notional re-investment of dividends. No financial performance changes or comparative period data are presented in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Investor Verification Points
- Verify the vesting schedule and conditions for the Performance Share Plan to understand when the notional dividends become payable.
- Confirm the final dividend payment date of July 10, 2008, and the actual payout amounts once the three-year measurement period concludes.
- Review the specific holdings of the listed directors (e.g., Dr. JP Garnier, Mr. A P Witty) to assess alignment with company performance.